Profile data is unavailable for this security.
About the company
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
- Revenue in EUR (TTM)271.36m
- Net income in EUR-16.93m
- Incorporated1988
- Employees415.00
- LocationPharming Group NVDarwinweg 24LEIDEN 2333 CRNetherlandsNLD
- Phone+31 715247400
- Fax+31 715247445
- Websitehttps://www.pharming.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jiangsu Recbio Technology Co Ltd | 0.00 | -72.09m | 495.08m | 507.00 | -- | 4.47 | -- | -- | -1.23 | -1.23 | 0.00 | 1.88 | 0.00 | -- | -- | 0.00 | -25.33 | -- | -32.84 | -- | -- | -- | -- | -- | 0.9619 | -- | 0.4548 | -- | -- | -- | 20.86 | -- | -- | -- |
| Pharming Group N.V. | 271.36m | -16.93m | 500.49m | 415.00 | -- | 2.33 | -- | 1.84 | -0.0265 | -0.0265 | 0.4405 | 0.316 | 0.663 | 0.524 | 6.44 | 653,887.80 | -4.14 | 5.26 | -4.99 | 6.63 | 89.39 | 89.41 | -6.24 | 9.26 | 2.76 | -4.84 | 0.3601 | -- | 19.30 | 9.01 | -177.14 | -- | -13.04 | -- |
| Gufic BioSciences Ltd | 91.57m | 9.71m | 502.31m | 1.45k | 51.23 | -- | 43.19 | 5.49 | 8.70 | 8.70 | 81.95 | -- | -- | -- | -- | 5,624,707.00 | -- | 11.46 | -- | 19.21 | 52.39 | 45.79 | 10.60 | 10.46 | -- | 8.09 | -- | 1.31 | 16.80 | 18.12 | 8.07 | 31.46 | 53.83 | 14.87 |
| ASP Isotopes Inc | 2.18m | -25.68m | 505.48m | 76.00 | -- | 35.41 | -- | 231.87 | -0.628 | -0.628 | 0.0549 | 0.2112 | 0.068 | -- | -- | 30,206.32 | -71.81 | -- | -89.44 | -- | 36.54 | -- | -1,055.85 | -- | -- | -8.11 | 0.6748 | -- | -- | -- | -229.34 | -- | -- | -- |
| Hunan Warrant Pharmaceutical Co Ltd | 189.98m | 27.78m | 505.65m | 1.16k | 18.21 | 2.05 | -- | 2.66 | 2.25 | 2.25 | 15.42 | 20.06 | 0.6426 | 1.49 | 9.74 | 1,244,707.00 | 8.34 | 11.21 | 9.79 | 14.05 | 61.32 | 69.00 | 12.98 | 13.96 | 3.18 | -- | 0.0566 | 8.05 | 10.84 | 18.50 | 15.60 | 19.02 | 24.49 | -- |
| Jeena Sikho Lifecare Ltd | -1.12bn | -1.12bn | 505.73m | 1.23k | -- | 142.27 | -- | -- | -- | -- | -- | 12.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.8228 | -- | 0.2681 | -- | 43.84 | -- | 77.37 | -- | -- | -- |
| Ocumension Therapeutics | 40.78m | -42.42m | 506.85m | 477.00 | -- | 1.18 | -- | 12.43 | -0.5303 | -0.5303 | 0.5097 | 4.30 | 0.103 | 2.40 | 2.48 | 752,654.60 | -10.71 | -38.78 | -11.55 | -41.47 | 58.29 | 62.30 | -104.01 | -975.82 | 5.00 | -- | 0.0055 | -- | 54.99 | -- | 5.68 | -- | 319.66 | -- |
| Soho Global Health Tbk PT | 577.37m | 26.52m | 520.71m | 2.31k | 19.63 | 3.35 | 17.02 | 0.9019 | 34.89 | 34.89 | 759.55 | 204.34 | 1.95 | 5.84 | 5.27 | 4,062,337,000.00 | 8.94 | 7.97 | 16.19 | 14.37 | 15.48 | 19.39 | 4.59 | 4.65 | 1.25 | -- | 0.0047 | -- | 12.45 | 12.43 | 4.10 | 49.70 | 21.21 | -- |
Data as of Nov 15 2024. Currency figures normalised to Pharming Group NV's reporting currency: Euro EUR
12.23%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RTW Investments LPas of 18 Jan 2024 | 20.03m | 2.95% |
| Acadian Asset Management LLCas of 23 Mar 2023 | 18.81m | 2.77% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 10.61m | 1.56% |
| DWS Investment GmbHas of 06 Feb 2024 | 9.95m | 1.47% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 7.71m | 1.14% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 5.00m | 0.74% |
| Healthinvest Partners ABas of 31 Dec 2023 | 3.95m | 0.58% |
| BlackRock Advisors (UK) Ltd.as of 03 Oct 2024 | 2.79m | 0.41% |
| KBC Asset Management NVas of 30 Jun 2024 | 2.10m | 0.31% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 2.03m | 0.30% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
